TomCharlesworth biomodalUnited Kingdom

TomCharlesworth
A biochemist by training, Tom leads the product management team at biomodal. This allows him to understand the technical aspects of duet evoC and the scientific questions the 6-base genome can unlock.

Tuesday 09 June 2026

Time Session
13:30
14:15
biomodal Industry Symposium: Get it all in one workflow: Use duet cfDNA solutions to detect cancer earlier, monitor treatment response and understand tumour biology
This session, sponsored by biomodal, will introduce the duet cfDNA solutions as complete integrated genetic and epigenetic workflows and software. The duet cfDNA solutions unlock the broadest spectrum of biomarkers, with market leading accuracy, from a single low input cfDNA sample, enabling ultra-low LoD for the detection of ctDNA. Talks will demonstrate how, in a liquid biopsy setting, 6-base data detects cancers earlier than other methylation sequencing approaches across multiple cohorts. Additional data will show how 6-base data enables a better understanding biological mechanisms of prostate cancer treatment response than existing liquid biopsy approaches.
  • TBC
    duet cfDNA solutions are complete integrated genetic and epigenetic workflows and software that unlock the broadest spectrum of biomarkers from a single low input cfDNA sample. The workflows have been engineered for cfDNA applications to maximise the recovery of unique cfDNA molecules. Coupled with the full complement of biomarkers on each DNA fragment, duet cfDNA enables ultra-low LoD for the detection of ctDNA. The solution provides market-leading 6-base genetic and epigenetic accuracy, including the ability to distinguish 5mC from 5hmC, coupled with fragmentomic information. Providing a full complement of biomarkers on each DNA fragment enables ultra-low LoD for the detection of ctDNA. 6-base data has been shown to detect cancer earlier than other methylation sequencing approaches in multiple cohorts. Furthermore, analysis of cfDNA from a combination therapy clinical trial has demonstrated the power of the 6-base genome for better understanding the biological mechanism of prostate cancer treatment response.
    TomCharlesworth Industry Speaker biomodalUnited Kingdom
Room F6+7+8